Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 19, Number 7—July 2013
Letter

Verona Integron–encoded Metallo-β-Lactamase 1 in Enterobacteria, Ontario, Canada

Nathalie Tijet, Gregory Macmullin, Olga Lastovetska, Christie Vermeiren, Patricia Wenzel, Tina Stacey-Works, Donald E. Low, Samir N. Patel, and Roberto G. MelanoComments to Author 
Author affiliations: Public Health Ontario Laboratories–Toronto, Toronto, Ontario, Canada (N. Tijet, G. Macmullin, O. Latovetska, D.E. Low, S.N. Patel, R.G. Melano); University of Toronto, Toronto (O. Lastovetska, D.E. Low, S.N. Patel, R.G. Melano); Shared Hospital Laboratory, Toronto (C. Vermeiren); Halton Healthcare Services, Oakville, Ontario, Canada (P. Wenzel, T. Stacey-Works); Mount Sinai Hospital, Toronto (D.E. Low, R.G. Melano)

Main Article

Table

VIM-1–producing Escherichia coli and Enterobacter cloacae clinical isolates, derivative transconjugants, and transformants, Ontario, Canada*

Characteristic E. coli GN531 E. cloacae GN719 E. cloacae GN738 E. cloacae GN825 E. coli J-531 E. coli T-719 E. coli T-825 E. coli Top10 E. coli J53
Drug, MIC (mg/L)†
Ampicillin ≥256 ≥256 ≥256 ≥256 ≥256 ≥256 ≥256 3 6
Cefoxitin ≥256 ≥256 ≥256 ≥256 64 ≥256 ≥256 6 8
Ceftazidime ≥256 ≥256 ≥256 ≥256 ≥256 ≥256 ≥256 0.19 0.19
Cefotaxime ≥256 ≥256 ≥256 ≥256 96 128 ≥256 0.094 0.094
Cefepime 256 32 192 256 12 12 24 <0.016 0.064
Ertapenem 2 2 8 24 0.125 0.25 0.25 0.004 0.008
Meropenem 1.5 6 6 16 0.5 0.5 0.5 0.023 0.023
Imipenem 4 6 6 8 2 2 1.5 0.19 0.38
Aztreonam ≥256 0.19 4 1.5 192 0.125 0.125 0.125 0.125
Amikacin 8 2 3 2 3 1.5 1.5 2 1.5
Gentamicin 96 12 2 96 4 0.75 2 0.064 1.5
Tobramycin 32 48 6 32 12 4 4 0.25 1
Nalidixic acid ≥256 ≥256 ≥256 ≥256 32 2 1 1 3
Ciprofloxacin ≥32 ≥32 ≥32 ≥32 0.5 0.125 <0.002 <0.002 0.012
Levofloxacin ≥8 ≥32 ≥32 8 0.5 0.094 0.002 0.003 0.016
Tetracycline ≤4 192 2 256 0.5 32 32 0.75 1
Tigecycline 0.094 1 0.5 1 0.047 0.064 0.094 0.032 0.047
Colistin 0.064 0.094 0.094 0.125 0.047 0.023 0.016 0.016 0.047
Co-trimoxazole ≥32 ≥32 ≥32 ≥32 ≥32 ≥32 0.047 0.023 0.064
Drug resistance gene‡
blaVIM-1 + + + + + + + NA NA
blaCTX-M-15 + NA NA
blaTEM-1 + + NA NA
blaACC-1 + + NA NA
blaOXA-1 like + NA NA
blaSHV-12 + + NA NA
qnrS1 + + + + + NA NA
Replicon type§
IncN + + + + + + NA NA
IncFrep + + + NA NA
IncFIB + + NA NA
IncFIA + NA NA

*VIM-1, Verona integron–encoded metallo-β-lactamase 1; E. coli J-531, E. coli transconjugant derived from GN531; E. coli T-719 and T-825, E. coli transformants derived from GN719 and GN825, respectively; E. coli J53 and TOP10, recipient E. coli J53 and TOP10, respectively; bla, β-lactamase; +, positive; NA, not applicable (only genes and replicons detected by molecular screening are included); –, negative; qnr, quinolone resistance; Inc, incompatibility.
†Drug susceptibility results were determined by using Etest (bioMérieux, Marcy l’Etoile, France) and the agar dilution method and interpreted by using Clinical and Laboratory Standards Institute guidelines (3).
‡Sequencing of whole genes was performed in samples positive by PCR. PCR included screening for blaTEM; blaSHV; blaOXA-1-like; blaCTX-M groups 1, 2, and 9; blaVEB; blaPER; blaGES; blaOXA-48-like; blaIMP; blaKPC; blaNDM-1; and 6 groups of blaAmpC genes (4).
§Obtained by using the replicon typing approach of Carattoli et al. (5).

Main Article

References
  1. Centers for Disease Control and Prevention. Update: detection of a Verona integron-encoded metallo-β-lactamase in Klebsiella pneumoniae—United States, 2010. MMWR Morb Mortal Wkly Rep. 2010;59:1212 .PubMed
  2. Giske  CG, Gezelius  L, Samuelsen  Ø, Warner  M, Sundsfjord  A, Woodford  N. A sensitive and specific phenotypic assay for detection of metallo-β-lactamases and KPC in Klebsiella pneumoniae with the use of meropenem disks supplemented with aminophenylboronic acid, dipicolinic acid and cloxacillin. Clin Microbiol Infect. 2011;17:5526 . DOIPubMed
  3. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 20th Informational supplement M100–S20. Wayne (PA): The Institute; 2010.
  4. Tijet  N, Alexander  DC, Richardson  D, Lastovetska  O, Low  DE, Patel  SN, New Delhi metallo-β-lactamase, Ontario, Canada. Emerg Infect Dis. 2011;17:3067 . DOIPubMed
  5. Carattoli  A, Bertini  A, Villa  L, Falbo  V, Hopkins  KL, Threlfall  EJ. Identification of plasmids by PCR-based replicon typing. J Microbiol Methods. 2005;63:21928. DOIPubMed
  6. Wirth  T, Falush  D, Lan  R, Colles  F, Mensa  P, Wieler  LH, Sex and virulence in Escherichia coli: an evolutionary perspective. Mol Microbiol. 2006;60:113651. DOIPubMed
  7. Rogers  BA, Sidjabat  HE, Paterson  DL. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother. 2011;66:114. DOIPubMed
  8. Mantengoli  E, Luzzaro  F, Pecile  P, Cecconi  D, Cavallo  A, Attala  L, Escherichia coli ST131 producing extended-spectrum β-lactamases plus VIM-1 carbapenemase: further narrowing of treatment options. Clin Infect Dis. 2011;52:6901. DOIPubMed
  9. Barton  BM, Harding  GP, Zuccarelli  AJ. A general method for detecting and sizing large plasmids. Anal Biochem. 1995;226:23540. DOIPubMed

Main Article

Page created: May 24, 2013
Page updated: May 24, 2013
Page reviewed: May 24, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external